BRAINSTORM CELL THERAPEUTICS INC. Lease, Cost
BRAINSTORM CELL THERAPEUTICS INC. (BCLI) reported Lease, Cost of $279.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Operating Expenses
us-gaap:LeaseCost · last filed 2026-08-14
- BRAINSTORM CELL THERAPEUTICS INC. lease, cost for the quarter ending 2026-06-30 was $80.00K, a 55.06% decline year-over-year.
- BRAINSTORM CELL THERAPEUTICS INC. lease, cost for the quarter ending 2026-03-31 was $199.00K, a 21.34% increase year-over-year.
- BRAINSTORM CELL THERAPEUTICS INC. lease, cost for the quarter ending 2025-12-31 was $190.00K, a 43.79% decline year-over-year.
- BRAINSTORM CELL THERAPEUTICS INC. lease, cost for the quarter ending 2025-09-30 was $180.00K.
- BRAINSTORM CELL THERAPEUTICS INC. lease, cost for fiscal 2024 was $662.00K, a 49.77% decline from fiscal 2023.
- BRAINSTORM CELL THERAPEUTICS INC. lease, cost for fiscal 2023 was $1.32M, a 35.18% increase from fiscal 2022.
- BRAINSTORM CELL THERAPEUTICS INC. lease, cost for fiscal 2022 was $975.00K, a 64.76% decline from fiscal 2021.
- BRAINSTORM CELL THERAPEUTICS INC. lease, cost for fiscal 2021 was $2.77M, a 94.45% increase from fiscal 2020.
| Period end | Lease, Cost 3 month | Lease, Cost 3 month as first filed | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month | Lease, Cost 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $80.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $279.00K 10-Q · filed 2026-08-14 | $469.00K derived: sum of 3 quarters · filed 2026-08-14 | $649.00K derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2026-03-31 | $199.00K 10-Q · filed 2026-05-15 | $389.00K derived: sum of 2 quarters · filed 2026-08-14 | $569.00K derived: sum of 3 quarters · filed 2026-08-14 | $747.00K derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-12-31 | $190.00K derived: 10-Q 12 month − 10-Q 9 month · filed 2026-08-14 | $370.00K derived: sum of 2 quarters · filed 2026-08-14 | $548.00K derived: sum of 3 quarters · filed 2026-08-14 | $712.00K 10-Q · filed 2026-08-14 | ||
| 2025-09-30 | $180.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $358.00K derived: sum of 2 quarters · filed 2025-11-14 | $522.00K 10-Q · filed 2025-11-14 | $860.00K derived: sum of 4 quarters · filed 2026-03-31 | ||
| 2025-06-30 | $178.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $342.00K 10-Q · filed 2025-08-14 | $680.00K derived: sum of 3 quarters · filed 2026-03-31 | $680.00K derived: sum of 4 quarters · filed 2026-03-31 | ||
| 2025-03-31 | $164.00K 10-Q · filed 2025-05-15 | $502.00K derived: sum of 2 quarters · filed 2026-03-31 | $502.00K derived: sum of 3 quarters · filed 2026-03-31 | -$641.00K derived: sum of 4 quarters · filed 2026-03-31 | ||
| 2024-12-31 | $338.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $338.00K derived: sum of 2 quarters · filed 2026-03-31 | -$805.00K derived: sum of 3 quarters · filed 2026-03-31 | $662.00K 10-K · filed 2026-03-31 | ||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$1.14M derived: sum of 2 quarters · filed 2024-11-14 | $324.00K 10-Q · filed 2024-11-14 | $1.02M derived: sum of 4 quarters · filed 2025-05-15 | ||
| 2024-06-30 | -$1.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $324.00K 10-Q · filed 2024-08-14 | $1.02M derived: sum of 3 quarters · filed 2025-05-15 | $1.02M derived: sum of 4 quarters · filed 2025-05-15 | ||
| 2024-03-31 | $1.47M 10-Q · filed 2025-05-15 | $164.00K 10-Q · filed 2024-05-14 | $2.17M derived: sum of 2 quarters · filed 2025-05-15 | $2.17M derived: sum of 3 quarters · filed 2025-05-15 | ||
| 2023-12-31 | $699.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $699.00K derived: sum of 2 quarters · filed 2025-03-31 | $1.32M 10-K · filed 2025-03-31 | $1.47M 10-K · filed 2024-04-01 | ||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $619.00K 10-Q · filed 2024-11-14 | ||||
| 2023-06-30 | $619.00K 10-Q · filed 2024-08-14 | |||||
| 2022-12-31 | $975.00K 10-K · filed 2024-04-01 | $2.71M 10-K · filed 2023-03-30 | ||||
| 2021-12-31 | $2.77M 10-K · filed 2023-03-30 | |||||
| 2020-12-31 | $1.42M 10-K · filed 2022-03-28 | |||||
| 2019-12-31 | $1.30M 10-K · filed 2021-02-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| Pluri Inc. (PLUR) | $0.014B | ||
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |